|Day Low/High||146.33 / 152.94|
|52 Wk Low/High||90.14 / 196.00|
Shares of GW Pharmaceuticals surge following soaring sales of its marijuana-derived epilepsy drug that prompts two analysts to raise their stock-price targets.
The shares slumped amid concern about another Canadian cannabis company's regulatory issues.
The charts make ZYNE look bearish and not particularly attractive, so avoid.
Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.
Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.
Jim Cramer highlights companies that can grow so big they make their own destinies: Walmart, Amazon, Target, Costco and Home Depot.
Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.
Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.
Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?
The company's announcement comes ahead of an FDA's public hearing on the legalization of CBD-infused foods and beverages on Friday.
Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.
Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?
Jim Cramer's take on tariff troubles? Break out your stock shopping list and buy domestic companies that are doing well.
Jim Cramer weighs in on Take-Two Interactive, Lennox International, Nabors Industries, CH Robinson Worldwide, The Blackstone Group, FedEx and more.
The way I do that is by using buy-write option strategies.
Five top marijuana stocks and four CBD plays in this speculative space.
You may want to check out GW Pharmaceuticals and Elixinol Global Limited.
In its first report on cannabis companies, Melius says prices are high.
Jim Cramer lists the great stocks and the obvious winners he wishes he had talked about more.
My trading strategy for GWPH whether you are currently long or want to be.
And why I won't recommend any other stocks in these markets, right now.
Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.
GWPH is ready to float higher after some sideways consolidation.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
Jim Cramer weighs in on Brinks, Sangamo Biosciences, Medtronic, Fiat Chrysler, GW Pharmaceuticals, EPR Properties.
The main reason most cannabis-related concerns head north to list their shares is banking.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.